Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, boosting the price target to $104.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu has given his Buy rating due to a combination of factors that highlight Revolution Medicines’ promising future prospects. The company has initiated the RASolute 304 trial, which is significant as it targets resectable pancreatic ductal adenocarcinoma (PDAC) with a focus on disease-free survival as the primary endpoint. This trial, along with the ongoing RASolute 302 trial, underscores the company’s commitment to advancing its pipeline and achieving key milestones.
Furthermore, Revolution Medicines has demonstrated strong financial health, with $1.93 billion in cash and equivalents as of September 30, 2025, and additional potential capital from royalty agreements. The management’s confidence in their commercial readiness and strategic scaling efforts to support future launches further solidify the company’s position. These elements combined suggest a robust growth trajectory, justifying the Buy rating.
In another report released on November 3, RBC Capital also initiated coverage with a Buy rating on the stock with a $77.00 price target.